Arcutis Biotherapeutics I... (ARQT)
NASDAQ: ARQT
· Real-Time Price · USD
17.34
0.61 (3.65%)
At close: Sep 26, 2025, 11:05 AM
3.65% (1D)
| Bid | 17.34 |
| Market Cap | 2.08B |
| Revenue (ttm) | 263.46M |
| Net Income (ttm) | -93.27M |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -23.75 |
| Forward PE | 101.76 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 17.36 |
| Volume | 276,815 |
| Avg. Volume (20D) | 1,664,742 |
| Open | 16.84 |
| Previous Close | 16.73 |
| Day's Range | 16.71 - 17.35 |
| 52-Week Range | 8.03 - 18.15 |
| Beta | 1.94 |
| Ex-Dividend Date | n/a |
About ARQT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ARQT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ARQT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsArcutis Biotherapeutics Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+12.31%
Arcutis Biotherapeutics shares are trading higher ...
Unlock content with
Pro Subscription
7 months ago
+8.36%
Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
1 month ago · seekingalpha.com
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call TranscriptArcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Frank Watanabe - Corporate Participant Latha Vairavan - Corporate Participa...